Evidence map›Paper›PMID 41749834›Full record

ArticleCancers2026

Frequency Ranking of Imaging Biomarkers for Lung Cancer Risk Stratification Using a Hybrid Elastic Net Method.

Mohamed Jaber, Emmy Stevens, Nezamoddin N Kachouie

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohamed JaberDepartment of Mathematics and Systems Engineering, Florida Institute of Technology, Melbourne, FL 32901, USA.ORCID 0009-0002-4133-0025
Emmy StevensDepartment of Mechanical and Civil Engineering, Florida Institute of Technology, Melbourne, FL 32901, USA.
Nezamoddin N KachouieDepartment of Mathematics and Systems Engineering, Florida Institute of Technology, Melbourne, FL 32901, USA.ORCID 0000-0001-9397-1807

Funding

Florida Department of Health 25C15
6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, emphasizing the critical need for novel and robust biomarkers to improve prognostication and guide precision oncology. While traditional clinical variables such as tumor stage, age, and sex are routinely used for survival prediction, their prognostic performance is limited. Imaging biomarkers derived from radiomic analysis of advanced medical imaging have emerged as a promising class of noninvasive cancer biomarkers, enabling quantitative characterization of tumor phenotypes. In this study, we investigated the prognostic utility of radiomic imaging biomarkers, with a particular focus on the texture-based feature Busyness, and compared their performance against conventional clinical factors. Survival analyses demonstrated that Busyness achieved significantly stronger discrimination of survival outcomes than stage, age, or sex. Stratified analyses further showed that Busyness consistently remained a dominant predictor of survival across age and sex subgroups, whereas tumor stage alone provided limited prognostic separation. To address class imbalance and enhance model robustness, the Synthetic Minority Over-sampling Technique (SMOTE) was applied, further supporting the stability of the imaging biomarker findings. These results highlight the potential of radiomic imaging biomarkers as powerful prognostic tools in lung cancer and support their integration into clinical workflows. This work contributes to the growing landscape of new cancer biomarkers and provides a foundation for future studies integrating imaging biomarkers with molecular and genomic markers to achieve improved prognostic accuracy.

Indexed as

Busyness featurelung cancer stratificationmachine learning in oncologyprognostic modelingradiomic biomarkersSMOTE balancingsurvival analysis

Identifiers

PMID41749834
PMCPMC12939589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.